IMR-1A

Research use only, not for human use.

IMR-1A is the metabolite of IMR-1 which is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μMol/L.

IMR-1A is a metabolite of IMR-1. IMR-1A acts as Notch inhibitor and targeting gene transcription by disrupting Mam1 recruitment to chromatin.

——

IMR-1A (2 mg/kg (i.v.) and 100 mg/kg (i.p)) exhibits low systematic plasma clearance (CL = 7 mL/min/kg) with terminal elimination half-life (T1/2) of 2.22 h following a single i.v. administration. The normal liver blood flow in mice is 90 mL/min/kg and the Vss (volume of distribution) is ~4-fold. Plasma concentrations is quantifiable up to 24 h with Tmax of 0.50 h after i.p. administration. Animal Model:Male C57 BL/6 mice Dosage:2 mg/kg (i.v.) and 100 mg/kg (i.p)Administration:I.v. and i.p.Result:Exhibited low systematic plasma clearance (CL = 7 mL/min/kg) with terminal elimination half-life (T1/2) of 2.22 h following a single i.v. administration and plasma concentrations isquantifiable up to 24 h with Tmax of 0.50 h after i.p. administration.

IMR-1A | IMR 1A | Inhibitor of Mastermind Recruitment-1 Acid

Others

Other Targets

Notch

Cancer

——

331862-41-0

325.36

C13H11NO5S2

>98% (HPLC)

DMSO : ≥ 31 mg/mL; 95.28 mM

O=C(O)COc1ccc(/C=C/2\SC(=S)NC2=O)cc1OC

2-[2-Methoxy-4-[(Z)-(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]phenoxy]acetic acid

(-20℃)

With Ice Pack

≥ 2 years